TL;DR - Q2 2026 revenue: $22.97B (+48% YoY), beating Wall Street consensus of $20.73B by $2.24B - Non-GAAP EPS: $8.38 (+33%), crushing $6.07 estimate by $2.31 (38% upside) - Mounjaro + Zepbound combined GLP-1 revenue: $14.87B (+73% YoY) - 2026 full-year revenue guidance raised to $85–$87B (midpoint +$2.5B vs prior $82–$85B) - Additional $4.5B committed to Indiana manufacturing expansion - Retatrutide (triple agonist) on track for FDA BLA submission Q1 2027
Part A: What the SEC 8-K Discloses
Eli Lilly and Company (NYSE: LLY) filed an 8-K with the SEC on August 5, 2026 (accession no. 0000059478-26-000077) reporting second-quarter financial results under Item 2.02.
Revenue and Earnings
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total Revenue | $22,974M | $15,558M | +48% |
| U.S. Revenue | $14,400M | — | +33% YoY |
| International Revenue | $8,600M | — | +80% YoY |
| Gross Profit | $19,706M | — | 85.8% margin |
| Operating Income | $8,978M | — | +31% |
| R&D Expense | $3,819M | — | +14% (17% of rev.) |
| Net Income (GAAP) | $7,095M | $5,673M | +25% |
| EPS (GAAP) | $7.94 | $6.29 | +26% |
| EPS (Non-GAAP) | $8.38 | $6.31 | +33% |
Consensus vs. actuals: Non-GAAP EPS of $8.38 beat the $6.07 Street estimate by $2.31. Revenue of $22.97B exceeded the $20.73B consensus by $2.24B.
Product Revenue Breakdown
| Product | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Mounjaro (tirzepatide, diabetes) | $9,943M | $5,199M | +91% |
| Zepbound (tirzepatide, obesity) | $4,928M | $3,381M | +46% |
| GLP-1 Subtotal | $14,871M | $8,580M | +73% |
| Ebglyss (lebrikizumab) | $201M | $87M | +131% |
| Jaypirca (pirtobrutinib) | $192M | $123M | +56% |
| Kisunla (donanemab, Alzheimer's) | $167M | $49M | — |
| Omvoh (mirikizumab) | $102M | $75M | +36% |
| Foundayo (orforglipron, obesity) | $98M | — | New |
| Inluriyo | $75M | — | New |
Mounjaro geography: U.S. $4.8B, International $5.2B — the first quarter in which international revenue exceeded domestic U.S. sales, reflecting the drug's accelerating global uptake.
Updated 2026 Full-Year Guidance
| Metric | Previous | Updated |
|---|---|---|
| Revenue | $82–$85B | $85–$87B |
| Non-GAAP EPS | $35.50–$37.00 | $35.50–$36.50 |
| Non-GAAP Perf. Margin | 47.0–48.5% | 49.0–50.5% |
| Tax Rate | 18–19% | Unchanged |
EPS note: The non-GAAP EPS ceiling was trimmed from $37.00 to $36.50, reflecting $3.03 per share of acquired in-process R&D (IPR&D) charges from five acquisitions completed in Q2 (Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and three post-quarter infectious disease companies). Underlying business EPS improved by $2.78 per share.
Manufacturing Commitment
Lilly committed an additional $4.5 billion to expand Indiana manufacturing facilities and opened its first dedicated genetic medicine facility. This supplements the $750 million Ohio manufacturing partnership with Resilience announced July 31.
Pipeline Highlights (from 8-K Exhibit 99.1)
- Retatrutide (GIP/GLP-1/glucagon triple agonist): Complete Phase 3 data package for obesity, obstructive sleep apnea, and knee osteoarthritis; FDA BLA submission planned Q1 2027.
- Foundayo (orforglipron): Submitted for type 2 diabetes approval in the U.S., potentially adding a second indication to the April-approved obesity label.
- Ebglyss: FDA approved every-eight-week maintenance dosing for moderate-to-severe atopic dermatitis.
- VERVE-102 (PCSK9 base editor, genetic medicine): Single dose reduced LDL-C by up to 62% in clinical trial.
- Retevmo: 83% reduction in recurrence/death risk as adjuvant therapy for early-stage RET fusion-positive lung cancer.
CEO David A. Ricks: "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance. At the same time, Lilly is building for the future."
Part B: Investment Analysis
Why the Stock Gave Back Its Premarket Gain
LLY surged more than 5% in premarket trading before retreating to approximately $1,123 (−2.25%) by mid-morning. The dynamic illustrates the "beat-and-retreat" risk when expectations are already elevated: Wall Street had penciled in roughly $13B in combined GLP-1 quarterly revenue, and Lilly delivered $14.87B — a massive beat. But at the historically high multiples LLY trades at, even a blowout quarter can be met with profit-taking once the initial surprise is absorbed.
The EPS ceiling trim from $37.00 to $36.50 introduced a note of caution. On the surface the revised range looks unchanged at the floor, but the $0.50 ceiling reduction signals that the acquisition-driven IPR&D charges will weigh on headline earnings more than originally modeled.
The Mounjaro Geography Inflection
For the first time, Mounjaro's international revenue ($5.2B) overtook its U.S. revenue ($4.8B) in a single quarter. International tirzepatide pricing is generally lower than U.S. net pricing — yet volume growth is outrunning the price gap. Lilly has effectively transformed into a global GLP-1 franchise, reducing its regulatory and reimbursement concentration risk in any single market. The 80% international revenue growth (+$8.6B) underscores that non-U.S. markets are becoming a structural pillar of the growth story.
Foundayo: USD 98 Million Is a Beginning, Not a Ceiling
Foundayo (orforglipron), approved by the FDA in April 2026, generated $98M in its first commercial quarter. Analysts at Jefferies project Foundayo revenue could reach $1.6B in FY2026, implying a steep acceleration in H2 as insurance coverage expands.
The oral GLP-1 opportunity is structurally important: injectable GLP-1s face supply constraints and patient reluctance around self-injection. A small-molecule oral pill that can be taken any time of day without food restrictions targets a meaningfully larger addressable patient population than injectables alone. As a small molecule, Foundayo is also simpler to manufacture at scale than Novo Nordisk's peptide-based oral Wegovy.
Lilly's clinical edge is meaningful: In the Phase 3 ACHIEVE-3 trial, Foundayo showed 9.2% average body weight loss versus 5.3% for oral semaglutide (Novo's Rybelsus) — a nearly 2x efficacy advantage in direct comparison. Novo held a launch lead (oral Wegovy approved December 2025), but Lilly appears set to compete on both efficacy data and manufacturing scalability.
Retatrutide: The Next Major Catalyst
Retatrutide's planned FDA BLA submission in Q1 2027 is perhaps the single most important near-term pipeline catalyst for LLY shareholders. The triple agonist (GIP/GLP-1/glucagon) showed weight loss of approximately 22–24% in Phase 3 — superior to Zepbound's 17–22% and semaglutide's 15–17%. The expanded label applications — obstructive sleep apnea and knee osteoarthritis pain, in addition to obesity — broaden the commercial opportunity significantly beyond weight management.
If approved in 2027–2028, retatrutide could succeed or supplement Zepbound as Lilly's obesity flagship, sustaining the franchise's growth trajectory as competitive biosimilars eventually enter the market.
Manufacturing Buildout: Constraint Becomes Moat
The additional $4.5B Indiana commitment signals Lilly's confidence in durable GLP-1 demand. Both Lilly and Novo Nordisk have faced supply shortfalls that historically limited their ability to capture full demand. Expanding dedicated manufacturing converts a near-term production constraint into a long-term competitive moat — making it harder for future entrants to scale against an established supplier with billions already sunk into dedicated infrastructure.
H1 2026 Scorecard
| Metric | H1 2026 | H1 2025 | Change |
|---|---|---|---|
| Revenue | $42,773M | $28,286M | +51% |
| Net Income (GAAP) | $14,491M | $8,432M | +72% |
| EPS (GAAP) | $16.19 | $9.35 | +73% |
| Non-GAAP EPS | $16.94 | $9.69 | +75% |
H1 2026 alone ($42.8B) already represents 49% of Lilly's updated full-year guidance midpoint ($86B), implying approximately flat H1-to-H2 revenue — not an acceleration. That modest H2 profile is the realistic risk to watch.
Risks to Monitor
- IPR&D acquisition pace: Five acquisitions in Q2 alone, plus at least four more post-quarter. Sustained M&A will create recurring IPR&D charges that compress reported EPS.
- Zepbound net pricing pressure: Q2 U.S. Zepbound revenue grew on volume despite "a decline in net prices." If volume growth decelerates before pricing stabilizes, top-line momentum could slow.
- Novo Nordisk's oral Wegovy ramp: Novo's manufacturing expertise in peptide-based GLP-1s and its December 2025 first-mover advantage in oral obesity therapy should not be underestimated.
- Implied H2 guidance flat: The $86B midpoint guidance implies ~$43.2B in H2 versus $42.8B in H1 — roughly flat sequentially — suggesting conservative management guidance or a genuine plateau risk.
The Investor Takeaway
Lilly delivered a clean quarter by almost every measure: a $2.24B revenue beat, 85.8% gross margins, +31% operating income growth, and a third consecutive guidance raise. For long-horizon investors, the pipeline sequence — Foundayo oral ramp, retatrutide BLA in 2027, VERVE-102 cardiovascular gene editing, and continued Mounjaro/Zepbound globalization — offers multiple potential catalysts.
The analyst consensus of approximately $1,277 average 12-month price target (versus ~$1,123 current price) implies roughly 14% potential upside from current levels. That return profile is consistent with owning a dominant but premium-valued growth compounder where the central debate is whether GLP-1 demand sustains itself as market penetration deepens — or whether the oral pill era and next-generation triple agonists unlock a new growth chapter altogether.
Q2 2026 did not settle that debate. But it confirmed that Lilly's execution engine is operating at a historically high level.
Sources: - SEC 8-K Filing (0000059478-26-000077) — Exhibit 99.1 - Eli Lilly Q2 2026 Press Release — Lilly IR - Eli Lilly LLY Q2 2026 Earnings — CNBC - Lilly Q2 Results — PR Newswire - Foundayo Launch Analysis — Fierce Pharma - Eli Lilly Q2 2026 Beat — Quiver Quantitative
